Tirzepatide is a lab-made peptide that activates the receptors for two gut hormones, GIP and GLP-1, and is the active ingredient in Mounjaro and Zepbound.1,2 It is FDA-approved: Mounjaro for adults with type 2 diabetes, and Zepbound for long-term weight reduction and for moderate to severe obstructive sleep apnea in adults with obesity.1,2 In August 2026 FDA added a use for Mounjaro, lowering the risk of major cardiovascular events in adults with type 2 diabetes at high risk, based on a cardiovascular outcomes trial.6 FDA says compounded and other unapproved tirzepatide products are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before they are marketed.10
Tirzepatide at a glance
What it is
A GIP receptor and GLP-1 receptor agonist. The Zepbound label states that it selectively binds to and activates both receptors.1
FDA status
FDA-approved. Drugs@FDA lists Mounjaro (first approved May 13, 2022) and Zepbound (November 8, 2023). The Zepbound label carries a boxed warning about thyroid C-cell tumors seen in rats.1,4,5
Human evidence
Large randomized, placebo-controlled trials described in the Zepbound label, and a cardiovascular outcomes trial that FDA cites as the basis for a 2026 Mounjaro approval.1,6
Evidence strength
Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned
Publication update registered by Crossref. The existing review records source-integrity notices. Inspect their scope before interpreting the summary →Erratum ↗ Crossref metadata identifies the notice but does not by itself explain what wording changed.
What is tirzepatide?
Tirzepatide is a lab-made peptide that acts on the receptors for two hormones released by the gut: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).1
Drugs@FDA lists it as the active ingredient of two Eli Lilly brands: Mounjaro and Zepbound.4,5
How does tirzepatide work?
The Zepbound label states that tirzepatide binds to and activates both the GIP and GLP-1 receptors, and that GLP-1 is a physiological regulator of appetite and calorie intake.1
According to the label, nonclinical studies suggest GIP may further contribute to regulating food intake, and animal studies show tirzepatide reaching and activating brain regions involved in appetite.1
What do human studies show?
The Zepbound label describes two 72-week randomized, placebo-controlled weight trials: one of 2,539 adults without type 2 diabetes and one of 938 adults with type 2 diabetes. It reports a statistically significant reduction in body weight compared with placebo in both.1
The label notes that body weight at week 72 was missing for some participants, up to 21.6% in one placebo group, and that missing values were imputed.1
Two 52-week trials in 469 adults with obesity and moderate to severe obstructive sleep apnea found a statistically significant reduction in the apnea-hypopnea index compared with placebo, according to the label.1
FDA’s August 2026 letters describe SURPASS-CVOT, a trial comparing tirzepatide with dulaglutide on major adverse cardiovascular events in adults with type 2 diabetes, conducted in adults with established cardiovascular disease.6,7
What the evidence base contains
Large randomized human trial A 72-week randomized, double-blind, placebo-controlled weight trial (NCT04184622) that enrolled 2,539 adults with obesity, or overweight with a weight-related condition, and excluded type 2 diabetes.1
Large randomized human trial A 72-week randomized, double-blind, placebo-controlled weight trial (NCT04657003) in 938 adults with type 2 diabetes and overweight or obesity.1
Controlled human trial Two 52-week randomized, double-blind, placebo-controlled sleep apnea trials (NCT05412004) that together enrolled 469 adults with obesity.1
Large randomized human trial SURPASS-CVOT, which compared tirzepatide with dulaglutide on major adverse cardiovascular events in people with type 2 diabetes. FDA’s August 2026 letter cites it as the basis for the new Mounjaro indication.6,7
Yes. Drugs@FDA records list Mounjaro’s original approval on May 13, 2022 and Zepbound’s on November 8, 2023.4,5
FDA’s November 2023 announcement describes Mounjaro as approved, along with diet and exercise, to improve blood sugar in adults with type 2 diabetes.2
The Zepbound label cited here (DailyMed SPL version 40, published September 2, 2026) states that Zepbound is indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain the reduction long term in adults with obesity, or overweight with a weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.1
On August 27, 2026, FDA approved a Mounjaro supplement adding a new indication: reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in adults with type 2 diabetes who are at high risk for them. The same letter records label changes to the warning on diabetic eye complications, based on SURPASS-CVOT.6
A Zepbound supplement effective August 26, 2026 added the SURPASS-CVOT results to the Zepbound prescribing information, with the same eye-complication warning change, according to FDA’s corrected approval letter. It did not add a cardiovascular indication for Zepbound, and the Zepbound label version cited here does not yet include that change.1,7
The Zepbound label carries a boxed warning: tirzepatide caused thyroid C-cell tumors in rats, and it is unknown whether it causes such tumors, including medullary thyroid carcinoma, in humans. The label states that Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.1
Other warnings in the label cover severe gastrointestinal reactions, kidney injury from fluid loss, gallbladder disease, acute pancreatitis, allergic reactions, low blood sugar, diabetic eye complications in people with type 2 diabetes and aspiration during anesthesia or deep sedation.1
In January 2026, FDA asked the makers of Saxenda, Wegovy and Zepbound to remove a warning about suicidal thoughts and behavior from their labels, after its review found no increased risk with GLP-1 medicines.8
FDA states that compounded drugs are not FDA-approved and that it does not review them for safety, effectiveness or quality before they are marketed. Its page on unapproved GLP-1 drugs, current as of October 1, 2026, describes fraudulent compounded tirzepatide whose labels name pharmacies that do not exist or did not make the product.10
The same page reports more than 730 adverse-event reports associated with compounded tirzepatide received as of May 31, 2026, and describes products falsely labeled as being for research purposes or not for human consumption.10
On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list used by outsourcing facilities, saying it found no clinical need for them to compound these drugs from bulk substances. FDA invited comments through June 29, 2026.9
Timeline
FDA approves Mounjaro, the first tirzepatide product, according to Drugs@FDA.4
FDA approves Zepbound for chronic weight management.2,5
FDA asks the makers of Saxenda, Wegovy and Zepbound to remove a suicidal thoughts and behavior warning from their labels.8
FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.9
FDA approves a Zepbound label update adding SURPASS-CVOT results, according to its corrected approval letter.7
FDA approves a new Mounjaro indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk.6
DailyMed publishes the Zepbound label version cited on this page.1
FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.10
What is still unknown?
Whether tirzepatide causes thyroid C-cell tumors in humans, which the label says has not been determined.1
Whether a cardiovascular benefit extends to people without type 2 diabetes: the new cardiovascular indication described in FDA’s letter covers adults with type 2 diabetes at high cardiovascular risk.6
What is in compounded, counterfeit or so-called research products, which FDA says it does not review before they reach the market.10
Whether FDA will finalize its April 2026 proposal on the 503B bulks list, which remained a proposal in the sources reviewed through November 14, 2026.9
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Tirzepatide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Tirzepatide are the records PeptideScanner has selected and published, not every registration or paper about Tirzepatide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence questions
Start with the question you have
Open the cited status, reviewed human evidence, unresolved limits, or profile changes.
FDA-approved as Mounjaro and Zepbound. The Zepbound label covers weight reduction and obstructive sleep apnea in adults with obesity and carries a boxed warning about thyroid C-cell tumors in rats. FDA’s August 2026 letters add a cardiovascular indication for Mounjaro and SURPASS-CVOT results to both labels. FDA says compounded and other unapproved tirzepatide products are not FDA-approved.↗↗↗↗↗↗
A bounded review of two sponsor-funded randomized Phase 3 trials: one in adults with obesity without diabetes and one in adults with type 2 diabetes treated with diet and exercise alone.↗↗
What the reviewed sources report
The reviewed obesity trial reported greater weight reduction with tirzepatide than placebo, and the reviewed type 2 diabetes trial reported lower glycated hemoglobin and body weight than placebo. These trials do not answer every population, long-term outcome, or post-discontinuation question.↗↗
What remains unresolved?
What are the durability, post-discontinuation outcomes, and uncommon harms across broader populations and longer follow-up?↗↗
The cited Zepbound label covers long-term weight reduction in adults with obesity, or overweight with a weight-related condition, and moderate to severe obstructive sleep apnea in adults with obesity. Both indications are described alongside diet and physical activity. This is a product-specific account, separate from Mounjaro labeling. Label: 1 ↗
Which safety limits matter?
The boxed warning reports thyroid C-cell tumors in rats, with uncertain human relevance. Contraindications include a personal or family history of medullary thyroid carcinoma, MEN 2 and serious hypersensitivity. Warnings address severe gastrointestinal reactions, kidney injury from volume depletion, gallbladder disease, pancreatitis, hypoglycemia, diabetic retinopathy complications and aspiration during anesthesia or deep sedation. Label: boxed warning, 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Label ZIP SHA-256: 4fe25d4173ba662adc2b4ac0653c09643bc7a9e883557286abe2c5d36f19d87e. Extracted XML SHA-256: 7c40611952c42e85d4688669dae2a5529cd563e0e857fdb23e411a8f7d8b0f14.
A bounded review of two sponsor-funded randomized Phase 3 trials: one in adults with obesity without diabetes and one in adults with type 2 diabetes treated with diet and exercise alone.12
Bottom line from this bounded source set
The reviewed obesity trial reported greater weight reduction with tirzepatide than placebo, and the reviewed type 2 diabetes trial reported lower glycated hemoglobin and body weight than placebo. These trials do not answer every population, long-term outcome, or post-discontinuation question.12
Reviewed study record
SURMOUNT-1 obesity trial
Design
A double-blind, randomized, placebo-controlled Phase 3 trial assessed body-weight change over 72 weeks.1
Population
The trial randomized 2,539 adults with obesity, or overweight plus at least one weight-related complication, and excluded people with diabetes.1
Outcomes reported
Reported mean body-weight change at week 72 ranged from -15.0% to -20.9% across tirzepatide groups and was -3.1% with placebo. Gastrointestinal events were the most common adverse events, and discontinuation for adverse events was more frequent in the tirzepatide groups.1
Limitations
The sponsor-funded trial used a dose-escalation period, excluded diabetes, and does not by itself establish outcomes after treatment stops or uncommon harms over longer periods.1
Reviewed study record
SURPASS-1 type 2 diabetes trial
Design
A double-blind, randomized, placebo-controlled Phase 3 trial assessed glycated hemoglobin, body weight, safety, and tolerability over 40 weeks.2
Population
The trial randomized 478 adults with type 2 diabetes inadequately controlled by diet and exercise who had not previously used injectable diabetes therapy.2
Outcomes reported
Reported mean glycated-hemoglobin change ranged from -1.87 to -2.07 percentage points across tirzepatide groups and was +0.04 with placebo. Reported body-weight reduction ranged from 7.0 to 9.5 kilograms, and gastrointestinal events were the most frequent adverse events.2
Limitations
The sponsor-funded trial was limited to 40 weeks and a treatment-naive type 2 diabetes population. Crossref also registers a publisher erratum for this publication; metadata alone does not describe the corrected wording.2
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2206038. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Publication update registered by CrossrefErratum ↗ · publisher metadata · July 17, 2021. Crossref metadata identifies the notice but does not by itself explain what wording changed.
On January 13, 2026, FDA requested removal of the suicidal-behavior and ideation warning from Zepbound labeling after its review found no increased risk. This records the agency’s request, not a claim that every label version has changed. FDA PDF pp. 1 ↗
More findings and the sources behind them
Selected FDA safety communications, read alongside the separately preserved product-label account and human evidence review.
What supported that finding
FDA combined 91 placebo-controlled trials involving 107,910 participants and examined a separate Sentinel claims cohort. These are class-wide analyses, not a dedicated trial of this peptide or a finding about every possible adverse effect. FDA PDF pp. 2, 3 ↗
Reports about compounded products need context
FDA reports adverse events associated with compounded tirzepatide, while noting underreporting and uncertain causality. Raw report totals do not establish an incidence rate or a fair comparison with approved products. FDA source ↗
What remains to be checked
Reconcile each current product and formulation label with subsequent safety and indication changes.
Appraise remaining eligible trial reports and follow-up studies; this update does not complete the literature review.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
EMA’s July 2022 assessment covers SURPASS-1 through SURPASS-5 in type 2 diabetes. Placebo comparisons were blinded, while several active-comparator trials were open-label and used different background therapies. EMA PDF pp. 203 ↗
More findings, study links and document coverage
An effect estimate depends on what happened after discontinuation
The review distinguishes an analysis including treatment changes and nonadherence from an efficacy analysis assuming intended treatment without rescue. These address different questions and should not be merged into one headline estimate. EMA PDF pp. 204 ↗
Comparisons apply to the regimens actually studied
The assessment found greater glycemic and weight improvements than its studied comparators, including the then-studied semaglutide regimen. This does not establish superiority over every formulation, regimen, population or later trial. EMA PDF pp. 203, 204 ↗
Important populations were sparsely represented
EMA noted limited clinical evidence in severe kidney or liver impairment, alongside gastrointestinal adverse effects and treatment discontinuations. This original diabetes assessment is distinct from later weight-management and other indication reviews. EMA PDF pp. 205, 211 ↗
Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.
One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗
Inspect documents, application identities and source pins
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
European medicine records · 1 products or applications
EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.
Active substance as listed: tirzepatide. EMA record ↗
Marketing authorisation: 2022-09-15. EMA metadata last updated 2026-08-28. EMA metadata ↗
Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
2536 retrieved · 2 included · 0 excluded · 2534 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Tirzepatide"[Title/Abstract] OR "LY3298176"[Title/Abstract] OR "Zepbound"[Title/Abstract] OR "Mounjaro"[Title/Abstract]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
Linked correction notices require comparison with the selected reports: PMID34274062 for PMID34186022. Their presence does not establish what changed.
Showing 25 of 2536 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 35658024 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT04184622.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 34186022 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT03954834.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed links an erratum: Department of Error. ↗. Impact on the selected study summary remains unresolved.
Notice XML SHA-256 77b4137f3d2d133936904bcae84dd9ceb73746fc92a75dcbfd9962b1a50ac157.
PubMed 42738922 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42736522 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42736027 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42735883 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42735880 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42735799 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42734711 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42733229 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42733128 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42732962 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42732434 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42730869 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42730175 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42730051 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42729958 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42729808 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42729636 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42728528 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42727867 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42727208 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42723821 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42722006 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42721915 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
2 retrieved · 2 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 2 of 2 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
FDA NDA217806 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TIRZEPATIDE.
FDA NDA215866 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TIRZEPATIDE.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EMEA/H/C/005620 — include: EMA feed product Mounjaro; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
27 retrieved · 14 included · 0 excluded · 13 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 25 of 27 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 56782 — include: Document linked by EMA product number; content unappraised. Mounjaro : EPAR - Public assessment report
EMA 62228 — include: Document linked by EMA product number; content unappraised. Mounjaro-H-C-PSUSA-00011019-202211 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 62456 — include: Document linked by EMA product number; content unappraised. Mounjaro-H-C-005620-II-0007 : EPAR - Assessment report - Variation
EMA 56780 — include: Document linked by EMA product number; content unappraised. Mounjaro : EPAR - All authorised presentations
EMA 65380 — include: Document linked by EMA product number; content unappraised. Mounjaro-H-C-PSUSA-00011019-202311 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 66627 — include: Document linked by EMA product number; content unappraised. Mounjaro-H-C-005620-II-0027 : EPAR - Assessment report - Variation
EMA 67371 — include: Document linked by EMA product number; content unappraised. Mounjaro-H-C-PSUSA-00011019-202405 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 57804 — include: Document linked by EMA product number; content unappraised. Mounjaro : EPAR - Procedural steps taken and scientific information after authorisation (archive)
EMA 56778 — include: Document linked by EMA product number; content unappraised. Mounjaro : EPAR - Medicine Overview
EMA 75020 — include: Document linked by EMA product number; content unappraised. Mounjaro-H-C-005620-II-0038 : EPAR - Assessment report - Variation
EMA 75019 — include: Document linked by EMA product number; content unappraised. Mounjaro-VR-0000281937 : EPAR - Assessment report - Variation
EMA 56779 — include: Document linked by EMA product number; content unappraised. Mounjaro : EPAR - Product Information
EMA 71029 — include: Document linked by EMA product number; content unappraised. Mounjaro : EPAR - Product information - tracked changes
EMA 67859 — include: Document linked by EMA product number; content unappraised. Mounjaro : EPAR - Procedural steps taken and scientific information after authorisation
EMA 55640 — not screened: Title-name match awaiting identity and document review. CHMP summary of positive opinion for Mounjaro
EMA 60836 — not screened: Title-name match awaiting identity and document review. CHMP post-authorisation summary of positive opinion for Mounjaro (II-07)
EMA 66099 — not screened: Title-name match awaiting identity and document review. Questions and answers on the outcome of assessment on use of Mounjaro in treatment of obstructive sleep apnoea
EMA 64106 — not screened: Title-name match awaiting identity and document review. P/0285/2023 : EMA decision of 24 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tirzepatide (Mounjaro), (EMEA-002360-PIP02-22-M01)
EMA 62016 — not screened: Title-name match awaiting identity and document review. P/0033/2023 : EMA decision of 31 January 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tirzepatide (Mounjaro) (EMEA-002360-PIP02-22)
EMA 58712 — not screened: Title-name match awaiting identity and document review. P/0174/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for tirzepatide (EMEA- 002360-PIP01-18-M02)
EMA 58171 — not screened: Title-name match awaiting identity and document review. P/0540/2021 : EMA decision of 31 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for tirzepatide (EMEA-002360-PIP01-18-M01)
EMA 47070 — not screened: Title-name match awaiting identity and document review. P/0311/2019: EMA decision of 10 September 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tirzepatide (EMEA-002360-PIP01-18)
EMA 66804 — not screened: Title-name match awaiting identity and document review. P/0478/2023 : EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tirzepatide (Mounjaro), (EMEA-002360-PIP02-22-M02)
EMA 71723 — not screened: Title-name match awaiting identity and document review. CHMP post-authorisation summary of positive opinion for Mounjaro (EMAVR0000281937)
EMA 72384 — not screened: Title-name match awaiting identity and document review. Questions and answers on the outcome of assessment on use of Mounjaro in treatment of heart failure with preserved ejection fraction in adults with obesity
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
303 retrieved · 0 included · 0 excluded · 303 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 25 of 303 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT06606821 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07697391 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06994338 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07194317 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07382180 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07555730 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07720466 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06914154 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05812183 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06467604 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07299084 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07423247 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06584916 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07756359 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06732245 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06790225 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06515418 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04050670 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06373146 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06779929 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05708859 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04004988 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03311724 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05990374 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05564039 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Tirzepatide?
FDA-approved as Mounjaro and Zepbound. The Zepbound label covers weight reduction and obstructive sleep apnea in adults with obesity and carries a boxed warning about thyroid C-cell tumors in rats. FDA’s August 2026 letters add a cardiovascular indication for Mounjaro and SURPASS-CVOT results to both labels. FDA says compounded and other unapproved tirzepatide products are not FDA-approved.↗↗↗↗↗↗
The cited status sources were checked through August 14, 2026. This answer changes only through the profile’s visible version and correction history.
All four evidence lanes appear in this selected collection, but their presence does not establish completeness, agreement, research quality, safety, effectiveness, approval, availability, or suitability.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Status at observationRecruiting 26Not yet recruiting 16Active, not recruiting 10Completed 6Enrolling by invitation 2
A phase value is unavailable here for 54 selected records; this is not counted as “no phase.”
A status value is unavailable here for 48 selected records; this is not counted as a trial status.
PubMed bibliography
Publication composition
33 of 75 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesJournal Article 24Letter 6Editorial 2Preprint 2Published Erratum 2Review 2Case Reports 1Clinical Trial, Phase III 1Comment 1Meta-Analysis 1Multicenter Study 1Observational Study 1Randomized Controlled Trial 1Systematic Review 1
Bibliography fields unavailable here for 42 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
2
FDA Federal Register documents
8
DailyMed SPL versions
22
Canonical profile
Published
Profile structured data
Published
Linked dated records
219
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsTrial–publication links · 1
These links come only from structured NCT and PMID identifiers declared by PubMed or ClinicalTrials.gov. They do not summarize the publications or establish findings.
PubMed lists PMID 43035094 in JAMA as Journal Article, with publication-date metadata of 2026-11-15 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
ClinicalTrials.gov posted a newer version of NCT07463846, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
ClinicalTrials.gov posted a newer version of NCT07734792, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
Selected records span May 13, 2022 to November 15, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PubMed lists PMID 43035094 in JAMA as Journal Article, with publication-date metadata of 2026-11-15 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 43030521 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-10-28 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 43030785 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-11-06 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PeptideScanner retained ClinicalTrials.gov record NCT05433584 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.↗
PeptideScanner retained ClinicalTrials.gov record NCT05556512 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07481747 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07931235 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06162715 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was tirzepatide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07929571 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was tirzepatide.↗
PubMed lists PMID 43009382 in Obesity research & clinical practice as Journal Article, with publication-date metadata of 2026-11-10 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗